Bayer AG has won Chinese approval for Sunharbo (asundexian) to prevent recurrent stroke after a noncardioembolic ischemic stroke or high-risk transient ischemic attack, giving the German drugmaker the…
Bayer AG has won Chinese approval for Sunharbo (asundexian) to prevent recurrent stroke after a noncardioembolic ischemic stroke or high-risk transient ischemic attack, giving the German drugmaker the first global regulatory approval for a factor XIa inhibitor and an early lead in the closely watched anticoagulant class.
Source disclosure
This is a source-linked briefing. Read the original report from Bioworld .